Equality Impact Assessment (Guidance development) (PDF 82 KB)
History
A list of downloadable documents created during development.
Expected publication
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination
-
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination document
-
-
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: appraisal consultation
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: appraisal consultation
-
-
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: appraisal consultation document
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: equality impact assessment: scoping
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: equality impact assessment: scoping
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final scope
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final scope
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final scope (PDF 22 KB)
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final matrix
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final matrix
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final matrix (PDF 27 KB)
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: draft scope for consultation (pre-referral) - November 2013
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: draft scope for consultation (pre-referral) - November 2013
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: provisional matrix (pre-referral) - November 2013
-
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: provisional matrix (pre-referral) - November 2013
-